Mavorixafor (trihydrochloride)

Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively.Mavorixafor trihydrochloride can be used for the study of WHIM syndrome[1].

Product Specifications

CAS Number

[2309699-17-8]

Product Name Alternative

AMD-070 (trihydrochloride) ; AMD-11070 (trihydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CXCR; HIV

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/AMD-070-hydrochloride.html

Concentration

10mM

Purity

99.75

Solubility

DMSO : 150 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

[H]Cl.[H]Cl.[H]Cl.NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3

Molecular Formula

C21H30Cl3N5

Molecular Weight

458.86

Precautions

H302, H315, H319, H335

References & Citations

[1]Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53 (8) :3376-88.|[2]Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40 (1) :303-308.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

CXCR4; HIV-1

Citation 01

Am J Physiol Cell Physiol. 2025 Apr 1;328 (4) :C1260-C1278.|Oncol Rep. 2022 Apr;47 (4) :68.|Proc Natl Acad Sci U S A. 2025 Mar 18;122 (11) :e2425795122.|Biosci Rep. 2023 Dec 22;43 (12) :BSR20230981.|Br J Haematol. 2023 May;201 (3) :459-469.|Cell Mol Life Sci. 2024 Mar 13;81 (1) :132.|Patent. US20220273751A1.|PLoS One. 2016 Mar 21;11 (3) :e0151765.